FDA’s briefing did not identify human treatment evidence within its assessment. The current registered trial reports recruitment but no results. A reliable benefit or adverse-event rate is not established by a study protocol alone [8].
Mouse studies ran from 3 days to 12 weeks
The selected mouse experiments measured different outcomes over different periods. FDA summarizes short metabolic experiments and longer weight-gain studies [1]. The 20%between-group mouse weight difference after 8 weeks is not a demonstrated human weight-loss schedule [2].
| Study | Subjects | Length | What changed |
|---|---|---|---|
| Kim 2019 | Obese mice on a high-fat diet | 3 days | Blood glucose about 50% lower than untreated mice |
| Lee 2015 | 12-month-old mice | 7 days | Muscle insulin response back to young-mouse levels |
| Lee 2015 | Mice on a high-fat diet | 8 weeks | About 20% lower body weight than untreated mice |
| Lu 2019 | Mice after ovary removal | 12 weeks | Less weight gain than untreated mice |
| Reynolds 2021 | Older mice on a treadmill program | 2 weeks | Better muscle glucose use; humans were only sampled, not treated |
| NCT07505745 | 120 adults with prediabetes (planned) | 12 weeks | Not yet reported |
Sources: FDA briefing on MOTS-c, July 2026, and the PubMed record for each study; ClinicalTrials.gov. Doses are left out on purpose: a mouse dose does not translate to a human one.
Short mouse studies measured blood sugar and insulin response; longer ones measured weight [3] [4]. A 2021 study tracked treadmill performance in mice of different ages and only sampled people's own MOTS-c after exercise [5]. What the weight results do and don't show is covered in does MOTS-c burn fat.
Mouse timing doesn't carry over to people
A mouse result can't be turned into a human timeline, and with MOTS-c there is a specific reason for doubt. FDA identified no in-vivo pharmacokinetic study; a related experiment was done in a test tube: an anti-doping lab added MOTS-c to human whole blood and found it broke down into shorter fragments rapidly [6]. FDA drew the obvious question from that:
It remains to be determined whether exogenous administration of MOTS-c to humans can generate pharmacologically active concentrations of the peptide over time.[1]
The reviewed sources do not establish human in-vivo exposure or a dependable clinical timeline. Breakdown in laboratory blood does not by itself prove that the peptide has no biological effect in a person. How long it lasts in the body is covered in how long MOTS-c stays in your system.
The protocol’s dates are estimates
The registered placebo-controlled trial of MOTS-c in people started in February 2026. Hudson Biotech's phase 2 study plans to enroll 120 adults with prediabetes and overweight or obesity, with participants, staff, investigators and assessors all blinded [7].
- Main result: change in insulin sensitivity (the Matsuda index, from a glucose tolerance test) at 12 weeks.
- Safety: treatment-related side effects through 16 weeks.
- Other measures: HbA1c, fasting glucose and 2-hour glucose at 12 weeks, plus antibodies to the drug.
- Status: recruiting, with the primary phase estimated to finish February 14, 2027 and the full study in May 2028.
Even when it reports, the trial will say whether MOTS-c changed insulin sensitivity over 12 weeks in one group of adults. It will not say how fast anyone feels a difference, and it does not measure energy, sleep or aging [7].
The 4-to-12-week claims come from sellers, not studies
A claimed benefit timetable needs an appropriate human treatment study, not a mouse study duration or testimonial. The reviewed sources do not establish a reliable4-to-12-week wellness schedule for administered MOTS-c.
If a seller gives you a timeline, ask which human study it comes from. FDA's adverse-event database searches through March 2025 found no MOTS-c reports, which tells you how little anyone is tracking, not that it is harmless [1]. Safety is covered in is MOTS-c safe, and the legal status of buying it in can you buy MOTS-c legally. How this site reads FDA documents is set out in how we check.
The current NCT07505745 record lists 120 estimated participants, recruiting at a site in China, with no posted results. Structured primary outcomes are insulin sensitivity at 12 weeks and adverse events through 16 weeks. Its detailed narrative also names body weight and waist circumference, although those are absent from the structured outcome list. That reporting difference prevents a categorical claim that weight will not be measured [8].